Viatris’ Presbyopia Drug Clears Second Phase III Trial

Viatris’ presbyopia drug clears second Phase III trial

There are only two therapies approved for presbyopia in the US.The post Viatris’ presbyopia drug clears second Phase III trial appeared first on Clinical Trials Arena.

Opus Genetics Announces VEGA-3 Phase 3 Trial Met Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics announced positive topline results from VEGA-3, its second pivotal phase 3 trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia. The VEGA-3 trial met its primary endpoint, with a statistically significant 27.2% of participants treated with phentolamine ophthalmic solution 0.75% achieving a ≥15-letter improvement in binocular distance-corrected near visual acuity (DCNVA), with less than a 5-letter …

Opus, Viatris say presbyopia drug succeeds in Phase 3

Opus Genetics and Viatris' eye drug hit the primary endpoint in a Phase 3 study, putting them on track for an FDA filing by the end of the year. The phentolamine ophthalmic solution 0.75% program ...

Opus Genetics reports positive phase 3 results for phentolamine ophthalmic solution 0.75%

Phentolamine Ophthalmic Solution 0.75% is a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, administered as an eye drop for the treatment of presbyopia.